What’s the Buzz

Updated - On February 11, 2022, the U.S Food and Drug Administration (FDA) issued an emergency use authorization (EUA) for bebtelovimab, a new monoclonal antibody treatment for COVID-19 in adults and children 12 years and older. As the number of infected cases increases daily, the authorization for bebtelovimab comes as great news since the FDA ceased the use of two other monoclonal antibody treatments as of January 22, 2022. Data has shown that the other two treatments—bamlanivimab and etesevimab (administered together) and REGEN-COV (casirivimab and imdevimab)—are unlikely to be effective against the COVID-19 omicron variant. 

What you need to know about bebtelovimab:

• It is a monoclonal antibody therapy that is effective against the omicron variant. 
• Like other monoclonal antibodies, bebtelovimab are lab-made proteins that mimic the immune system’s ability to fight harmful